Outcomes of Cerebral Embolic Protection for Bicuspid Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Replacement
Jiajun Zhang, Xiaoxing Li, Rui Tian, Mengzhi Zong, Xinghua Gu, Feng Xu, Yuguo Chen, Chuanbao Li
Abstract
Background There was limited high‐quality evidence that illuminated the efficiency of cerebral embolic protection (CEP) use during transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve (BAV) stenosis. Methods and Results In this retrospective cohort study, patients with BAV stenosis undergoing TAVR with or without CEP were identified by querying the National Inpatient Sample database. The primary end point was any stroke during the hospitalization. The composite safety end point included any in‐hospital death and stroke. We applied propensity score–matched analysis to minimize standardized mean differences of baseline variables and compare in‐hospital outcomes. From July 2017 to December 2020, 4610 weighted hospitalizations with BAV stenosis undergoing TAVR were identified, of which 795 were treated with CEP. There was a significant increase in the CEP use rate for BAV stenosis ( P ‐trend <0.001). A total of 795 discharges with CEP use were propensity score matched to 1590 comparable discharges but without CEP. CEP use was associated with a lower incidence of in‐hospital stroke (1.3% versus 3.8%; P <0.001), which in multivariable regression was also independently associated with the primary outcome (adjusted odds ratio=0.38 [95% CI, 0.18–0.71]; P =0.005) and the safety end point (adjusted odds ratio=0.41 [95% CI, 0.22–0.68] P =0.001). Meanwhile, no significant difference was found in the cost of hospitalization ($46 629 versus $45 147; P =0.18) or the risk of vascular complications (1.9% versus 2.5%; P =0.41). Conclusions This observational study supported CEP use for BAV stenosis, which was independently associated with less in‐hospital stroke without burdening the patients with a high hospitalization cost.